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To better direct repair following spinal cord injury (SCI), we
designed an implant modeled after the intact spinal cord consisting
of a multicomponent polymer scaffold seeded with neural stem
cells. Implantation of the scaffold–neural stem cells unit into an
adult rat hemisection model of SCI promoted long-term improve-
ment in function (persistent for 1 year in some animals) relative to
a lesion-control group. At 70 days postinjury, animals implanted
with scaffold-plus-cells exhibited coordinated, weight-bearing
hindlimb stepping. Histology and immunocytochemical analysis
suggested that this recovery might be attributable partly to a
reduction in tissue loss from secondary injury processes as well as
in diminished glial scarring. Tract tracing demonstrated corticospi-
nal tract fibers passing through the injury epicenter to the caudal
cord, a phenomenon not present in untreated groups. Together
with evidence of enhanced local GAP-43 expression not seen in
controls, these findings suggest a possible regeneration compo-
nent. These results may suggest a new approach to SCI and, more
broadly, may serve as a prototype for multidisciplinary strategies
against complex neurological problems.
Each year approximately 10,000 Americans sustain spinal cordinjuries (SCI). Functional deficits following SCI result from
damage to or severance of axons, loss of neurons and glia, and
demyelination. SCI pathology is determined not only by the
initial mechanical insult, but also by secondary processes includ-
ing ischemia, anoxia, free-radical formation, and excitotoxicity
that occur over hours and days following injury (1). Central
nervous system (CNS) axonal regeneration appears to be im-
peded partly by myelin-associated inhibitors (1, 2), loss in adult
neurons of an intrinsic ability to overcome inhibitory cues (3),
and formation of a post-lesion scar barrier (4). However, if axons
can traverse the injury site, there is evidence that they may
regrow in unscarred regions (5, 6). Furthermore, preservation of
even a small percentage of tissue significantly enhances func-
tional recovery (7). Although there have been encouraging
reports of deficit reduction (8–10) and axonal regrowth by
blocking inhibitory molecules and antagonizing secondary injury
mechanisms (11); myelin replacement by stem (12), Schwann
(13), and olfactory ensheathing cells (14, 15); delivery of growth
factors (16–18) and small molecules (19); and implantation of
fetal tissue (19) and scaffolds (20–23), as yet there is no practical
treatment for SCI.
We sought a conceptually new approach that simulated the
architecture of the healthy spinal cord through an implant
consisting of a polymer scaffold seeded with neural stem cells
(NSCs) modeled after the gray and white matter of the intact
cord (Fig. 1a). The scaffold’s inner portion emulated the gray
matter via a porous polymer layer designed to be seeded with
NSCs (24) for cellular replacement as well as trophic support
(Fig. 1 b and c).†† The outer portion emulated the white matter
with long, axially oriented pores for axonal guidance and radial
porosity to allow fluid transport while inhibiting ingrowth of scar
tissue (Fig. 1d). The scaffold is designed to be tailored to fit into
a variety of cavities. In this study, the scaffold was tailored to fit
into the cavity created by a midline lateral hemisection in the
spinal cord of an adult rat. We hypothesized that this multicom-
ponent, degradable, synthetic scaffold of specified architecture
seeded with NSCs might mitigate secondary injury, impede glial
scar formation, direct cell replacement, facilitate regeneration,
and guide repair to create a more physiologically relevant
structure.
Methods
Scaffold Fabrication. Both the inner and outer scaffolds were
fabricated from a blend of 50:50 poly(lactic-co-glycolic acid)
(PLGA) (75%, number average molecular weight, Mn, 40,000)
and a block copolymer of poly(lactic-co-glycolic acid)-polylysine
(25%, PLGA block Mn  30,000, polylysine block Mn  2000).
The PLGA was chosen to achieve a degradation rate of about
30–60 days, and the functionalized polymer was incorporated to
provide sites for possible surface modification. The inner scaf-
fold was made using a salt-leaching process: a 5% (wtvol)
solution of the polymer blend in chloroform was cast over salt
with a diameter range of 250–500 m, and the solvent was
allowed to evaporate. The salt was then leached in water. The
oriented outer scaffold was fabricated using a solid–liquid phase
separation technique (25) in the following way: A 5% (wtvol)
solution of the polymers was filtered and injected into silicone
tubes which were lowered at a rate of 2.6  104 ms into an
ethanoldry ice bath. Once frozen, the dioxane was sublimated
using a shelf temperature-controlled freeze drier (VirTis). The
scaffolds were then removed, trimmed, assembled, and stored in
a vacuum desiccator until use.
Cell Maintenance and Seeding. Murine NSCs (clone C17.2) were
maintained in serum-containing medium (24). Scaffolds were
soaked in 70% ethanol for 24 h, rinsed three times in PBS, and
seeded on an orbital shaker with 5  105 cellsml at 37°C in a
humidified 5% CO2air incubator. The medium was changed the
next day, and the implants were incubated for 4 more days before
implantation. For the cells-alone control, 10 l of a 107 cellsml
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suspension was injected into the cavity following the hemisec-
tion. No gelfoam or other means were used to maintain the cells
in the cavity because this was thought to introduce a confounding
variable.
Surgical Procedures and Animal Care. Fifty adult female Sprague–
Dawley rats were used. Animals were anesthetized with a 4%
chloral hydrate solution (360 mgkg i.p.). Using a dissecting
microscope, a laminectomy was made at the 9th-to-10th thoracic
(T9-T10) spinal vertebrae, followed by a lateral hemisection at the
T9-T10 level by creating a 4-mm-long longitudinal cut along the
midline of the cord with a No. 11 surgical blade, followed by
lateral cuts at the rostral and caudal ends and removal of the
tissue by aspiration. The surgical blade was repeatedly scraped
along the ventral surface of the vertebral canal, followed by
aspiration to remove any residual fibers at the lesion site. After
gelfoam-triggered hemostasis occurred, an independent blinded
observer confirmed the adequacy of the length and breadth of
the lesion. Only at that time was the surgeon informed of the
treatment (previously prepared) to be administered to the lesion.
The lesion was affirmed a priori to be similar across all exper-
imental groups and animals.
Either the full treatment, consisting of insertion of the NSC-
seeded scaffold (‘‘scaffold plus cells,’’ n  13; Fig. 1e), or one of
three control treatments was performed: (a) polymer implant
without NSCs (‘‘scaffold alone,’’ n  11; (b) NSCs suspended in
medium (‘‘cells alone,’’ n 12); or (c) hemisection alone (‘‘lesion
control,’’ n  12).
Surgeries were performed in a randomized block design. The
surgeries for the implant plus controls were performed on the
same day to minimize differences between groups arising from
any refinement in surgical technique during the study, and the
order was varied each day to reduce surgical bias. Hemisections
were alternated between the right and left sides to further reduce
bias. Following either the full or control treatment, the muscu-
lature was sutured, skin closed, and the animal recovered in a
clean cage on a heating pad. Ringer’s lactate solution (10 ml) was
given daily for 7 days post-op and bladders were evacuated twice
daily until reflex bladder function was established.
Because immunosuppressive agents such as cyclosporin A
have been shown to be neuroprotective on their own (26), these
experiments were performed without such neuroimmunophilins
to avoid this confounding variable. Donor cells were nevertheless
present at the end of the study.
A separate group of scaffold plus cells animals underwent the
same procedures as above and were maintained for one year.
All procedures were reviewed and approved by the Animal
Care and Use Committee of Children’s Hospital, Boston.
Behavioral Studies and Statistical Evaluation. One day postinjury
(p.i.) and weekly thereafter, behavioral analysis was performed
by two observers blinded to the treatments, using a battery of
tests to rate open-field locomotion by the Basso–Beattie–
Bresnahan (BBB) scale (27); the ability to maintain body
position on an inclined plane; and contact righting reflex and
spinal cord-mediated hindlimb withdrawal to pain (28). Behav-
ioral tests were performed at the same time each day and graded
by the same blinded observers. For the inclined plane test, the
highest degree of inclination was defined as being that at which
the animal could maintain its position for 5 s on two separate
trials (29). Contact righting and limb withdrawal to pain were
performed according to Gale et al. (28). One animal died
following surgery because of an overdose of chloral hydrate. The
remaining 49 animals survived and exhibited no signs of auto-
phagia throughout the course of the study. One animal was
excluded from the analysis because it showed incomplete paral-
ysis at 1 day post-op. The Kolmogorov–Smirnov goodness-of-fit
test was used to determine the normality (Gaussian-shaped
distribution) of the data. The BBB data showed no significant
departure from a normal distribution for all time points beyond
day 1, so parametric methods were used including repeated-
measures analysis of variance (ANOVA) and Bonferroni post
hoc analysis for multiple group comparisons to determine the
statistical significance of the results. The inclined plane data
showed a significant departure from a normal distribution and
was analyzed with the Kruskal–Wallis H-test, followed by the
Mann–Whitney U test to identify specific group differences when
the Kruskal–Wallis test showed significance (P  0.05).
Tissue Processing for Histology. Following perfusion, spinal cords
were carefully dissected, postfixed overnight in 4% paraformal-
dehyde, dehydrated overnight at 4°C in 30% sucrose, and frozen
in isopentane. Two centimeter blocks of the thoracic region of
the cords including injury epicenters were embedded in OCT
and cryosectioned. Longitudinal sections for hematoxylineosin
(H&E) were obtained from a depth of 1.6 mm into the cord
(from the dorsal side). Neurofilament sections were 80 m
dorsal to H&E sections.
BDA Tracing. BDA (biotinylated dextran amine; Molecular Probes,
10% wtvol solution) was injected at ten points in the sensory motor
cortex contralateral to the side of the spinal cord hemisection at or
beyond 70 days p.i. (30). Animals were maintained for 4 more weeks
then killed. Following cryosectioning of the tissue, BDA was
revealed histochemically on mounted sections by using a Vector
Elite ABC kit (Vector Laboratories) followed by development with
DAB and light counterstaining with neutral red.
Immunocytochemistry. Immunocytochemistry was performed on
20-m mounted sections employing the following antibodies:
anti-neurofilament 200 (NF) (Sigma; 1:200); anti-glial fibrillary
acidic protein (GFAP; Sigma; 1:80); M2 (a mouse-specific
marker; gift from Carl Lagenaur, University of Pittsburgh; 1:5);
anti-GAP-43 (gift from Larry Benowitz, Children’s Hospital,
Boston; 1:50,000). Briefly, sections were incubated with primary
antibody for 1 h at 37°C followed by the appropriate secondary
antibody for 1 h at 37°C. Blocking solution consisted of 3%
Fig. 1. (a) Schematic of the scaffold design showing the inner and outer
scaffolds. (b and c) Inner scaffolds seeded with NSCs. (Scale bars: 200 m and
50 m, respectively.) The outer section of the scaffold was created by means
of a solid–liquid phase separation technique that produced long, axially
oriented pores for axonal guidance as well as radial pores to allow fluid
transport and inhibit the ingrowth of scar tissue (d; scale bar, 100 m). (e)
Schematic of surgical insertion of the implant into the spinal cord.
Teng et al. PNAS  March 5, 2002  vol. 99  no. 5  3025
M
ED
IC
A
L
SC
IE
N
CE
S
serum in which the secondary antibody was raised and 5% BSA
(Vector Laboratories).
Results and Discussion
Fig. 2 a and b shows the mean BBB open-field walking scores
(27) for the four experimental groups on their ipsilateral,
‘‘lesioned’’ (Fig. 2a), and contralateral, ‘‘unlesioned’’ (Fig. 2b)
sides. The open-field locomotion of representative animals from
the scaffold plus cells and lesion-control groups who performed
near the mean of their groups at day 70 is shown in Movie 1,
which is published as supporting information on the PNAS web
site, www.pnas.org. Open-field locomotion on both the ipsilat-
eral and contralateral sides in the scaffold plus cells group was
significantly enhanced in the subchronic phase (up to 28 days
p.i.) with respect to both rate and absolute level of improvement
achieved; this enhanced performance was maintained into the
chronic phase of recovery (70 days p.i.). Performance of the
unlesioned side mirrored the lesioned side both in absolute mean
values achieved and statistical significance. Impairment of the
contralateral side likely reflects the severity of the hemisection
(see surgical procedures for details) in which 4 mm of tissue was
removed, leading to severance of a number of blood vessels that
may have resulted in ischemia- and hypoxia-related secondary
injury on the unlesioned side. Similar phenomena have been
reported (31). Both hindlimbs were affected, and recovery of
both was improved by the scaffold plus cells intervention. The
scaffold plus cells group, in the late chronic stage (i.e., 56 days
p.i. and later), achieved a stabilized mean BBB score of approx-
imately 12, which corresponds to frequent-to-consistent weight-
supported plantar-stepping and occasional forelimb-hindlimb
coordination. In contrast, the cells-alone and lesion-control
groups only achieved stabilized mean BBB scores of 6 and 7,
respectively. Encouragingly, the scaffold-alone group also
achieved a mean BBB score of 9, which indicates the onset of
weight-supported locomotion, suggesting that even the scaffold
alone is capable of leading to improvement in functional recov-
ery. Defining the onset of significant walking behavior as
achieving a BBB score of 10 or greater at 70 days p.i., 69% of the
Fig. 3. Hematoxylineosin (H&E) staining of representative 20-m-thick
longitudinal and transverse sections from each group. (a and b) Scaffold plus
cells sections in longitudinal and cross section, respectively. Area with an
asterisk in a is shown at higher power in c. (a) A section from the cord of the
scaffold plus cells animal from Movie 1, which is published as supporting
information. Although there is some degeneration of gray matter, there is
preserved tissue near the injury epicenter as well as rostral and caudal to the
injury. There is only limited scar tissue at the injury epicenter on the lesioned
side (c). (d–f ) Scaffold-alone sections. Area with an asterisk in e is shown at
higher power in d. (g and h) Cells-alone sections. Note the degradation of
tissue both rostral and caudal to the injury epicenter as well as the extent of
scar tissue at the injury epicenter on both the lesioned and unlesioned sides
(arrow). (i and j) Lesion-control sections. In i there is a small degree of white
matter on the unlesioned side, but the lesioned region has expanded almost
2-fold from the original lesion size, a 4-mm lateral hemisection. In j there is an
incomplete rim of peripheral white matter on the unlesioned side. (Scale bar,
2.5 mm.)
Fig. 2. (a) BBB open-field walking scores for the four groups on the ipsilat-
eral, lesioned side. Hindlimbs were assessed independently to determine the
degree of asymmetry. The rate of improvement for the scaffold plus cells
group was significantly greater than the rate for the cells-alone (P  0.001)
and lesion-control groups (P0.004; two-way repeated measures of ANOVA).
For absolute score attained, the scaffold plus cells group showed significant
improvement in open-field locomotion compared with the cells-alone (P 
0.006) and lesion-control groups (P0.007) for all time points from 14 days p.i.
on (ANOVA, Bonferroni post hoc analysis). (b) BBB open-field walking scores
for the contralateral unlesioned hindlimb. There is only a 1–2 point difference
between the lesioned (see a) and unlesioned sides, indicating that the walking
behavior of the groups was relatively symmetric overall and that both sides
were impacted by this unilateral lesion. Individual animals did, however,
exhibit a degree of asymmetry in their stepping with a twisted trunk position
leading to the rotation of both hindlimbs to one side of their bodies. (c)
Inclined plane results. When facing upwards, animals in the four groups are
statistically similar for all time points (Kruskal–Wallis test) indicating that they
were generally similar in strength. When facing downwards, the scaffold plus
cells group performance showed statistically significant improvement on all
days from day 14 on (except days 49 and 70) compared with the cells-alone and
lesion-control groups (Kruskal–Wallis test). Although the data showed signif-
icant departure from the Gaussian distribution, parametric analysis revealed
similar results to nonparametric analysis, and the results are represented in the
figure by their means for visual clarity. (d) Righting reflex results. The scaffold
plus cells group exhibited a significantly higher percentage of normal righting
on day 56 as compared with the lesion-control (Pearson 2 test of indepen-
dence). (e) Percent of animals with a normal pain reflex in response to toe
pinching was significantly higher in the plus cells group on the days marked by
the asterisks (Pearson 2 test). ( f) Percent of animals exhibiting a spastic
response to the same toe pinching stimuli.
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scaffold plus cells groups, 54% of the scaffold alone, but only
17% of the cells-alone and 33% of lesion-control groups attained
BBB score of at least 10.
For inclined plane performance, animals were tested facing
both upwards and downwards (Fig. 2c). Whereas performance in
the upward-facing orientation reflects forelimb strength, which
should be unaffected by this injury in healthy animals, perfor-
mance facing downwards measures coordinated hindlimb motor
function (28). In the upwards orientation, all groups exhibited
statistically similar performances, suggesting that the animals
had similar forelimb strength. However, the scaffold plus cells
group showed statistically significant improvement with respect
to the cells-alone and lesion-control groups in the downward-
facing orientation on all days beyond day 7 (except days 49 and
70). Overall, the inclined plane results mirror the BBB scoring,
suggesting that the scaffold plus cells intervention is associated
with significant long-term improvement of motor function.
Spinal cord mediated reflexes also showed a trend toward
improvement following the scaffold plus cells intervention as
compared with cells alone and lesion controls. In particular, a
higher percentage of animals in the scaffold plus cells group
exhibited normal righting behavior on all days beyond day 14
(Fig. 2d).
The scaffold plus cells group demonstrated more normal
sensory responses. Fig. 2e shows the percentage of animals after
SCI in each group with a normal pain withdrawal reflex induced
by a controlled brief pinch of the toes (28). At 70 days p.i.,
approximately 50% of the animals regained a normal pain
withdrawal reflex (scored as a 2 and representing an immediate
and controlled withdrawal reflex in response to the stimuli) on
the lesioned side in the groups treated with scaffolds plus cells
and scaffold alone (Fig. 2e). In contrast, only approximately 15%
of the cells-alone and lesion-control groups regained a normal
pain withdrawal reflex on the lesioned side. Fig. 2f shows the
percentage of animals with a spastic pain withdrawal reflex,
which is defined as an immediate but hyperactive response in
which the limb demonstrates spasms upon stimulation. Overall,
the scaffold plus cells and scaffold-alone interventions appear to
lead to a more favorable outcome of the normal, nonspastic
response, suggesting more normal spinal cord-mediated
reflexes.
Histology, tract tracing, and immunocytochemistry were per-
formed on all cords to help elucidate possible mechanisms
leading to the observed functional recovery. The images of the
lesion area presented in Fig. 3 are representative of each
experimental group at 120 days p.i., and were obtained from
animals whose BBB scores placed them near the mean of their
respective groups. The sections are all from the same depth at 1.6
mm into the cord. The cross sections were obtained through the
injury epicenter, which was determined by the least amount of
contralateral tissue sparing in each cord. The scaffold plus cells
(Fig. 3 a–c) and scaffold-alone cords (Fig. 3 d–f ) at 120 days p.i.
had very limited residual lesions that barely crossed the midline
of the cord (Fig. 3 a and c). In some cases, there appeared to be
newly formed tissue within the injury epicenter (Fig. 3 d and e).
The cells-alone (Figs. 3 g and h) and lesion-control cords (Fig.
3 i and j) demonstrated marked residual lesions 5–6 mm in length
and encompassing the majority of the width of the cord. Fur-
thermore, both the lesion-control and cells-alone cords exhibited
atrophy both rostral and caudal to the injury. In some of the
cells-alone and lesion-control cords, scar tissue and cysts were
seen. Fig. 3g, a longitudinal section of a typical cells-alone cord,
demonstrates the epidural scar tissue (marked by the arrow) as
well as the cyst formation seen in some of the cells-alone and
lesion-control cords, but not seen in the scaffold plus cells or
scaffold alone cords.
It is hypothesized that the scaffold may impede scarring and
subsequent cyst formation. The mechanism for this is not yet
Fig. 4. (a) BDA tracing of the corticospinal tract in a scaffold-alone animal. BDA was injected into the sensorimotor cortex contralateral to the spinal cord injury
at or beyond 70 days p.i. such that BDA-positive fibers would be visible at the site of, or caudal to, the spinal cord lesion if corticospinal tract fibers were present
and passing through the injury site. Arrows indicate where the tracer passes into the lesioned side of the cord. Note the tortuous path of the fibers (arrows; see
text). The rostral end is to the right, and the lesion cavity is on the bottom. (b) Positive BDA tracing caudal to the injury in the same cord as in a. (c) GAP-43, a
marker for regenerating axons, is positive in the same cord as seen in a and b just rostral to the injury. Likewise, scaffold plus cells cords exhibit BDA tracing with
the same tortuousity immediately (d) rostral to as well as (e) caudal to the injury, and (f) a large number of GAP-43-positive axons just rostral to the injury. The
cells-alone (g) and lesion-control cords (h) exhibit BDA staining rostral to the injury but not caudal, and there are minimal fibers positive for GAP-43 (i, cells alone;
j, lesion control; scale bars in a–b, d–e, and g–h, 10 m; in c, f, and i–j, 20 m).
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known but may be correlated with inhibition of cellular ingrowth
by the outer scaffold. In vitro, the outer scaffold appears to
inhibit the ingrowth of a variety of cell types, including fibro-
blasts, into the porous scaffold for at least 2 weeks (data not
shown). The absence of scar formation is correlated with a
higher degree of tissue preservation at the injury epicenter as
well as preservation of tissue rostral and caudal to the epicenter.
The absence of scar tissue may account for the diminished
atrophy in the spinal cords of the scaffold-containing groups as
compared with the cells alone and lesion controls. The expansion
of the lesion has been correlated with secondary injury processes
(1), and the size of the lesion appears to correlate with the degree
of functional deficit (32).
Although tissue preservation appears to be the primary factor
accounting for the improved functional recovery in the scaffold
plus cells group, it may be augmented by possible regenerative
processes. BDA tracing of the corticospinal tract (30), coupled
with immunocytochemistry for GAP-43, a protein up-regulated
in the growth cones of regenerating axons (33), suggests that
there may be a component of regeneration occurring. Fig. 4 a
and b shows BDA tracing of the corticospinal tract on the
lesioned side of the cord in the scaffold-alone group. There is
positive tracing of fibers through the injury epicenter (Fig. 4a,
arrows) and caudal to the injury (Fig. 4b). For BDA-positive
corticospinal tract axons to be detectable in regions caudal to the
injury epicenter, BDA, injected in the motor cortex, had to have
been transported in an antegrade manner along either spared or
regenerated corticospinal fibers. The tortuous path of the traced
fibers as well as the multipolar nature of the portions caudal to
the injury site is most consistent with morphological profiles
generally seen in regenerating axons as opposed to spared fibers,
which would retain their straight, nontortuous profile. There are
a large number of GAP-43-positive fibers just rostral to the
injury site in this cord (Fig. 4c, arrows), further suggesting a
possible component of regeneration at day 70 p.i. Likewise, in
the scaffold plus cells cords, there was BDA-positive tracing both
rostral and caudal to the injury epicenter as well as GAP-43
immunopositive staining just rostral to the injury (Fig. 4 d–f ). In
contrast, the cells-alone and lesion-control cords showed posi-
tive BDA tracing rostral but not caudal to the injury epicenter
(Fig. 4 g and h), and very few GAP-43-positive fibers (Fig. 4 i and
j). BDA tracing plus GAP-43 immunostaining, though fre-
quently used indicators of regeneration (27), are not definitive
markers.
Both the scaffold plus cells and scaffold-alone cords exhibited
immunopositive staining for an antibody against neurofilament
(NF) within the injury epicenter (Fig. 5 a and b). In Fig. 5b, the
region of immunopositive staining is within the space of the
primary injury, suggesting that the newly formed tissue contains
neurons or neuronal elements. Fig. 5c shows immunohistology of
a scaffold plus cells cord just rostral to the injury epicenter
employing an NF-antibody (green) plus mouse-specific antibody,
M2 (red), to identify donor murine NSC-derived cells within the
rat host. Donor-derived cells were identified in both cells-alone
and scaffold plus cells cords rostral to the injury epicenter (Fig.
5c, red immunostaining). Confocal microscopy of the expression
pattern of these markers, however, suggests that the donor cells
were not immunopositive for NF, suggesting that the neurons
were actually of host origin. In comparison to the scaffold-
containing groups, the lesion-control cords showed much less
immunopositive staining for NF throughout the thoracic region
of the cord (Fig. 5d). Although the donor NSCs do not appear
to be immunopositive for NF, they are also not largely immu-
nopositive for GFAP (Fig. 5e), suggesting that they are not
contributing to the glial scar. The majority of the donor cells are,
in fact, immunopositive for nestin (Fig. 5f ), suggesting that they
remained largely undifferentiated. It is possible that the major
contribution of the NSCs was trophic support rather than cellular
replacement.†† Although there were substantially fewer donor-
derived cells in the cords receiving NSCs alone, the NSCs appear
to have behaved in a similar way, remaining largely nestin-
positive.
The functional results suggest that the scaffold played an
important role in recovery. Immunostaining for GFAP in the
scaffold-alone and lesion controls (Fig. 5 h and g) exhibited a
smaller population of astrocytes in the injury epicenter of the
former than of the latter. The lesion-control and cells-alone
cords, in general, exhibited larger populations of GFAP-positive
astrocytes at their lesion epicenters than the scaffold plus cells
and scaffold alone cords. Although controversial, astrocytes
have been correlated with formation of the inhibitory glial scar.
Thus, a reduction in astrocyte ingrowth following injury is
believed to be desirable. Although the mechanism by which the
scaffold may augment recovery is not known, in vitro evidence,
as noted above, suggests that the outer scaffold inhibits ingrowth
of a variety of cell types. Because the scaffold is completely
degradable, this inhibition is temporary. However, the outer
scaffold may reduce inflammatory cell infiltration that occurs
shortly after SCI, in turn reducing astrogliosis (34).
The mechanisms by which the scaffold and NSCs augment
functional recovery need to be explored further. A detailed
Fig. 5. All longitudinal sections. (a) A scaffold plus cells section at the injury
epicenter immunostained for NF (green) and counterstained with DAPI (blue).
(b) Scaffold-alone section at the injury epicenter exhibiting NF immunoreac-
tivity (green) within the region excised by the initial lesion, suggesting that the
new tissue contains neurons or neuronal elements (blue, DAPI). (c) Double
immunostaining for NF (green) and the mouse-specific antigen M2 used to
identify donor cells (red) in a scaffold plus cells cord and DAPI (blue). The cord
has extensive NF immunopositivity, but there is no clear colocalization of NF
and M2, suggesting that the NF cells were of host-origin. (d) There are few
NF cells near the injury epicenter in the lesion-control cord. (e) Scaffold plus
cells section doubled-immunostained for GFAP (green) and M2 (red). The
majority of donor-derived cells (red) are not double-labeled for GFAP, sug-
gesting that they do not contribute to the astroglial scar. ( f) Most donor cells
(stained with the M2 antibody, green in this figure) are double-labeled for
nestin (red in this figure), as seen by confocal microscopy. GFAP immunostain-
ing (green) in the spared tissue contralateral to the hemisection in a scaffold
plus cells cord (g) compared with a lesion-control cord (h). There is a far greater
incidence of astrocytes at the injury epicenter of the lesion-control compared
with the scaffold-alone cord. (Scale bars: a–f, 20 m; g–h, 10 m.)
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anatomical study at multiple time points correlated with the
current behavioral results (including quantitative analysis of cell
types involved and the number of myelinated and unmyelinated
axons) may help to elucidate some mechanisms. In addition,
because the corticospinal tract in the rat is not mainly involved
in locomotor function, regenerative activity in more relevant but
less accessible tracts (e.g., rubrospinal tracts) needs to be exam-
ined in future studies. Electrophysiology may allow a better
understanding of the nature of the neuroprotected tissue along
with any regenerated neural tissue at the injury site. The use of
additional animal models may also be helpful.
In summary, implantation of the scaffold with NSCs signifi-
cantly improves functional recovery as compared with cells alone
and lesion controls. Indeed, scaffold plus cell animals main-
tained for 1 year p.i. continue to show enduring recovery with
respect to BBB scoring (n  8). Although the scaffold alone
appears to play a significant role in functional recovery following
hemisection by reducing epidural and glial scar formation, the
combination of the NSCs and scaffold is critical for the greatest
recovery.
Satisfactory outcomes have not been achieved to date in
treating SCI by means of a single approach. Our results suggest
that, with further study, the concept of polymer scaffolds seeded
with NSCs may contribute to a new multifaceted approach for
the treatment of SCI. More broadly, this work may provide a
prototype for other multidisciplinary strategies for addressing
complex neurological maladies.
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